differences between glp-1 medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Injectable vs Oral GLP-1: Comparing

Some GLP-1 drugs appear more likely to cause gastrointestinal side effects than others

Since Mounjaro was licensed for use for weight management in the UK in 2023 it has become the most widely used weight-loss drug

Dose increase: Dose may be increased to 25 mg orally once a day for patients tolerating therapy and requiring additional glycemic control

In December 2024, several generic versions of liraglutide (Victoza) for the treatment of type 2 diabetes became commercially available in the United States, while an authorized generic (AG) version launched in the United States in June 2024

Substituting tirzepatide for semaglutide is a theoretical extension of that idea pairing an amylin analog with a more potent dual incretin agonist but it is important to repeat that this specific pairing has not been validated in a dedicated human combination trial